Skylar Jeremias

Shawn Kwatra, MD, dermatologist, John Hopkins University, recounts his study assessing the use of nemolizumab in prurigo nodularis presented at the American Academy of Dermatology conference.

An Italian review highlighted the potential of AI to enhance early diagnosis and treatment of hidradenitis suppurativa, though challenges such as data privacy, algorithm bias, and interpretability must be addressed to fully leverage AI's benefits in dermatology.

The FDA approved the first 2 biosimilars referencing aflibercept (Eylea). However, patent litigation has left it unclear when the biosimilars will come to market.

A recent study found significant regional disparities and a decline in inpatient dermatology encounters and providers across the US from 2013 to 2019, highlighting the need for increased support and improved access to specialized dermatologic care.

A recent study applied machine learning to medical and pharmacy claims data to develop a model for predicting hidradenitis suppurativa (HS) diagnosis, highlighting the potential for improved understanding of HS underdiagnosis on a health care system level.

According to a review, recent progress offers hope in the form of treatments, such as combination therapy that utilizes surgical and nonsurgical methods, for individuals with facial acne scars.

A literature review has found that ultraviolet radiation, rising temperature, and air pollution could be possible climate-related influences on skin cancer rates.

A recent study found that patients with actinic keratosis experienced more pain during red light photodynamic therapy (PDT) than simulated daylight PDT, emphasizing the need to understand patient experiences for better treatment decisions.

In a recent study, secukinumab therapy demonstrated adequate safety and efficacy profiles, offering potential benefits for patients with severe hidradenitis suppurativa (HS) who found adalimumab intolerable.

Patients with hidradenitis suppurativa (HS) in Canada often wait long periods of time to receive an HS diagnosis and receive evidence-based therapy, highlighting the need for increased interdisciplinary education on HS management.

A real-world study confirmed that the rate of adverse events associated with first-line nivolumab plus iplimumab therapy was in line with the safety profiles of other immuno-oncology and chemotherapy combination regimens.

Mike Brown, vice president of managed services at Cardinal Health, discusses Cardinal Health's goals to to leverage technology, while reducing costs to the health care system.

Mike Brown, vice president of managed services at Cardinal Health, discusses how remote pharmacy services are revolutionizing patient care by improving accessibility and medication safety.

Abstracts from the 65th American Society of Hematology (ASH) Annual Meeting and Exposition provided new insight into multiple treatments for patients with multiple myeloma (MM), chronic lymphocytic leukemia (CLL), and follicular lymphoma (FL).

Researchers found that venetoclax, either alone or post treatment with a Bruton tyrosine kinase inhibitor (BTKi), was safe and effective for patients with chronic lymphocytic leukemia (CLL).

Mike Brown, vice president of managed services at Cardinal Health, shares how drug cost control software has improved monitoring efficiency and reduced drug spending.

Mike Brown, vice president of managed services at Cardinal Health, discusses how Cardinal Health has worked to integrate key digital health solutions among hospitals across the United States.

Health care workers who received SARS-CoV-2 vaccinations were found to be protected against declines in respiratory parameters after overcoming COVID-19, highlighting the importance of COVID-19 vaccines for health care workers.

A recent study encapsulates how patients and caregivers characterize the impact of Duchenne muscular dystrophy (DMD) on patients’ physical limitations and symptom burden, potentially helping to inform patient-centered strategies for assessing clinical outcomes in DMD research.

Patients with spinal muscular atrophy (SMA) treated with a more expensive medication were found to have higher pharmacy costs but lower SMA-related health care resource utilization and medical costs compared with patients receiving standard-of-care nusinersen monotherapy.

A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.

A study investigating potential subtypes of idiopathic hypersomnia (IH) found that patients with IH who experience unrefreshing naps have less fragmented sleep compared with those who take refreshing naps, suggesting unrefreshing naps could serve as a supportive IH clinical feature.

A new survey from the National Alliance of Healthcare Purchaser Coalitions found that employers are planning to place a larger focus on obesity management, women’s health, and health equity in 2024 and beyond.

Bio-Thera Solutions’ Avzivi (bevacizumab-tnjn) has become the fifth biosimilar referencing Avastin (bevacizumab) to be approved in the United States.

A population-based study found that out-of-hospital cardiac arrest events resulting from drug overdoses have significantly increased from 2015 to 2021, particularly among patients who have taken a combination of stimulants and opioids.

Depression symptoms are often underdiagnosed and undertreated in patients with psoriasis and psoriatic arthritis, contributing to a worsened quality of life (QOL). However, a recent study found that depression, functional impairment, and worsened QOL are related.

The presence of cochlear dysfunction found in patients with alopecia areata (AA) suggests the need for more comprehensive assessment and management of hearing-related issues associated with AA.

A cohort study found that early changes in patient-reported outcomes (PROs) were associated with treatment response and survival outcomes in patients with advanced gastrointestinal cancer, supporting the need for more routine implementation of PRO monitoring in cancer care spaces.

A new report from IQVIA provides an overview of current US drug shortages, shedding light on major areas of concern, such as medications to address pain, cardiovascular conditions, obesity and diabetes, and multiple forms of cancer.

Dr. Parth Rali, MD, of Temple University Hospital explained the challenges of managing patients with intermediate-risk pulmonary embolism (PE) and how risk stratification tools can help to address these challenges.